Elsevier Inc.

SHERPA: Unknown

People

  1. Iyer
    Iyer
  2. Bochner
    Bochner
  3. Solit
    Solit
  4. Rosenberg
    Rosenberg
  5. Al-Ahmadie
    Al-Ahmadie
  6. Pietzak
    Pietzak
  7. Bajorin
    Bajorin
  8. Donahue
    Donahue
  9. Berger
    Berger
  10. Dalbagni
    Dalbagni

Groups

  1. Department of Medicine (26)
  2. Genitourinary Oncology Service (26)
  3. Solid Tumor Oncology Division (26)
  4. Surgery (15)
  5. Urology (14)
  6. GSK Faculty (11)
  7. Human Oncology and Pathogenesis Program (11)
  8. Epidemiology and Biostatistics (7)
  9. Sloan Kettering Institute Postdocs (7)
  10. Survivorship Research (6)
Search Within
  1. "Gopakumar Iyer"
  2. "Genitourinary Oncology Service"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (11)
  3. Review (4)
Groups
  1. Department of Medicine (26)
  2. Genitourinary Oncology Service (26)
  3. Solid Tumor Oncology Division (26)
  4. Surgery (15)
  5. Urology (14)
  6. GSK Faculty (11)

More Groups

People
  1. Gopakumar Iyer (26)
  2. Hikmat Al-Ahmadie (12)
  3. Bernard Bochner (11)
  4. David Solit (11)
  5. Jonathan Rosenberg (10)
  6. Eugene Pietzak (8)

More People

Years
  1. 2024 (6)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (3)
  5. 2020 (2)
  6. 2018 (5)

More Years

Publications
  1. Urologic Oncology: Seminars and Original Investigations (9)
  2. Clinical Genitourinary Cancer (5)
  3. European Journal of Cancer (5)
  4. Cancer Treatment and Research Communications (1)
  5. Gynecologic Oncology (1)
  6. Hematology/Oncology Clinics of North America (1)

More Publications

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ERBB2 alterations in non-muscle invasive bladder cancer are associated with a distinct genomic signature
    Meeting Abstract

    Alam, S. M.; Tallman, J.; Koll, F.; D'Souza, N.; de Jesus Escano, M.; Donahue, T.; Goh, A.; Sarungbam, J.; Berger, M.; Schultz, N.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Genomic characterization of high-grade Ta urothelial carcinoma with and without carcinoma in situ
    Meeting Abstract

    Tallman, J. E.; Alam, S. M.; Koll, F.; Baky, F. J.; D'Souza, N.; de Jesus Escano, M.; Donahue, T. F.; Goh, A. C.; Sarungbam, J.; Berger, M. F.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Comutational patterns in FGFR3-altered non-muscle invasive bladder cancer influence recurrence and progression
    Meeting Abstract

    D'Souza, N.; de Jesus Escano, M.; Alam, S. M.; Gao, S.; Tang, X.; Goh, A.; Bochner, B. H.; Solit, D.; Iyer, G.; Al-Ahmadie, H.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Carcinoma in situ and urinary cytology as an indicator of minimal residual disease in patients with non-muscle invasive bladder cancer treated with BCG
    Meeting Abstract

    Katims, A. B.; D'Souza, N.; De Jesus Escaño, M. R.; Gokturk, G.; Basar, M.; Solit, D. B.; Iyer, G.; Bochner, B. H.; Goh, A.; Donahue, T. A.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Clinical, molecular and immunohistochemical profiles of clear cell adenocarcinoma of the urinary tract
    Meeting Abstract

    Koll, F.; Rammal, R.; Chen, Z.; Basar, M.; Alam, S. M.; Tallman, J. E.; Pietzak, E.; Dalbagni, G.; Donahue, T.; Donat, S. M.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
    Journal Article

    Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
    Meeting Abstract

    Lee, E.; Rodon, J.; Demeure, M.; Deming, D.; Federman, N.; McKean, M.; Spira, A.; Kwiatkowski, D.; Hussein, M.; Gordon, E.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1
    Review

    Hensley, P. J.; Seiler, R.; Herr, H.; Mouw, K. W.; Iyer, G.; Dyrskjøt, L.; Nawroth, R.; Goebell, P.; Schmitz-Drager, B.; Todenhofer, T.; more...
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Systemic therapy in bladder preservation
    Review

    Girardi, D. M.; Ghatalia, P.; Singh, P.; Iyer, G.; Sridhar, S. S.; Apolo, A. B.
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 study of MLN0128 (TAK-228) in patients with tumors with TSC1 or TSC2 mutations: Sub-protocol EAY131-M
    Meeting Abstract

    Hays, J.; Song, Z.; Paik, P.; Iyer, G.; Mitchell, E.; Wright, J.; Doyle, L.; Gray, R.; Wang, V.; McShane, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save